Cencora, Inc. (NYSE:COR) Position Lowered by Diversified Trust Co

Diversified Trust Co lowered its stake in Cencora, Inc. (NYSE:COR - Free Report) by 5.6% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 48,559 shares of the company's stock after selling 2,867 shares during the quarter. Diversified Trust Co's holdings in Cencora were worth $10,930,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. purchased a new position in shares of Cencora during the 4th quarter worth $4,212,508,000. Price T Rowe Associates Inc. MD purchased a new position in shares of Cencora during the 1st quarter worth $2,183,619,000. JPMorgan Chase & Co. purchased a new position in shares of Cencora during the 1st quarter worth $1,199,695,000. Boston Partners purchased a new position in shares of Cencora during the 1st quarter worth $1,001,269,000. Finally, Capital Research Global Investors purchased a new position in shares of Cencora during the 1st quarter worth $650,424,000. Hedge funds and other institutional investors own 97.52% of the company's stock.

Cencora Stock Down 0.2 %

NYSE COR traded down $0.44 during trading hours on Monday, hitting $219.50. The company had a trading volume of 1,326,119 shares, compared to its average volume of 1,415,304. Cencora, Inc. has a fifty-two week low of $182.62 and a fifty-two week high of $247.66. The company has a market capitalization of $43.78 billion, a price-to-earnings ratio of 24.04, a P/E/G ratio of 1.58 and a beta of 0.44. The company has a debt-to-equity ratio of 3.93, a current ratio of 0.89 and a quick ratio of 0.55. The firm's 50 day moving average is $234.60 and its 200 day moving average is $232.07.

Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings results on Wednesday, July 31st. The company reported $3.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.18 by $0.16. Cencora had a return on equity of 266.60% and a net margin of 0.65%. The firm had revenue of $74.20 billion during the quarter, compared to the consensus estimate of $73.32 billion. During the same period in the prior year, the firm earned $2.92 EPS. The firm's quarterly revenue was up 10.8% compared to the same quarter last year. Sell-side analysts anticipate that Cencora, Inc. will post 13.63 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, August 26th. Investors of record on Friday, August 9th were issued a $0.51 dividend. The ex-dividend date was Friday, August 9th. This represents a $2.04 annualized dividend and a yield of 0.93%. Cencora's dividend payout ratio is currently 22.32%.

Insider Activity at Cencora

In related news, EVP Silvana Battaglia sold 1,473 shares of the stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $242.69, for a total value of $357,482.37. Following the completion of the sale, the executive vice president now directly owns 10,948 shares in the company, valued at approximately $2,656,970.12. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, EVP Silvana Battaglia sold 1,473 shares of the firm's stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $242.69, for a total transaction of $357,482.37. Following the completion of the sale, the executive vice president now directly owns 10,948 shares in the company, valued at $2,656,970.12. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Steven H. Collis sold 10,755 shares of the firm's stock in a transaction dated Tuesday, July 16th. The shares were sold at an average price of $222.12, for a total value of $2,388,900.60. Following the sale, the chief executive officer now owns 285,088 shares of the company's stock, valued at $63,323,746.56. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 4,450,399 shares of company stock worth $1,070,392,799. Corporate insiders own 15.80% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on COR. Bank of America reissued a "neutral" rating and set a $245.00 price target (down previously from $275.00) on shares of Cencora in a research note on Wednesday, September 18th. JPMorgan Chase & Co. increased their price target on Cencora from $280.00 to $287.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 21st. Leerink Partners dropped their price objective on Cencora from $277.00 to $275.00 and set an "outperform" rating for the company in a report on Monday. Robert W. Baird dropped their price objective on Cencora from $287.00 to $283.00 and set an "outperform" rating for the company in a report on Friday, September 6th. Finally, Wells Fargo & Company upped their price objective on Cencora from $236.00 to $249.00 and gave the stock an "equal weight" rating in a report on Thursday, August 1st. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat.com, Cencora currently has an average rating of "Moderate Buy" and a consensus price target of $256.67.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.